Format

Send to

Choose Destination
Front Cell Neurosci. 2016 Jun 28;10:164. doi: 10.3389/fncel.2016.00164. eCollection 2016.

Protection of Primary Dopaminergic Midbrain Neurons by GPR139 Agonists Supports Different Mechanisms of MPP(+) and Rotenone Toxicity.

Author information

1
Department of Neurodegeneration, H. Lundbeck A/S Valby, Denmark.
2
Department of Molecular Screening, H. Lundbeck A/S Valby, Denmark.
3
Department of Discovery Chemistry 2, H. Lundbeck A/S Valby, Denmark.

Abstract

The G-protein coupled receptor 139 (GPR139) is expressed specifically in the brain in areas of relevance for motor control. GPR139 function and signal transduction pathways are elusive, and results in the literature are even contradictory. Here, we examined the potential neuroprotective effect of GPR139 agonism in primary culture models of dopaminergic (DA) neuronal degeneration. We find that in vitro GPR139 agonists protected primary mesencephalic DA neurons against 1-methyl-4-phenylpyridinium (MPP(+))-mediated degeneration. Protection was concentration-dependent and could be blocked by a GPR139 antagonist. However, the protection of DA neurons was not found against rotenone or 6-hydroxydopamine (6-OHDA) mediated degeneration. Our results support differential mechanisms of toxicity for those substances commonly used in Parkinson's disease (PD) models and potential for GPR139 agonists in neuroprotection.

KEYWORDS:

G protein-coupled receptor; Parkinson’s disease model; apoptosis; cell-based assay; drug screening; neurodegeneration; neuroprotection; neurotoxin

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center